+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Brain Biomarkers Market (2021-2026) by Product, Indication, Application, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 175 Pages
  • November 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5503463
The Global Brain Biomarkers market is estimated to be USD 6.12 Bn in 2021 and is expected to reach USD 12.72 Bn by 2026, growing at a CAGR of 15.75%.



Market Dynamics

The increasing number of research and technological and development of biomarker-based clinical diagnostics has a high prevalence of brain disorders amongst the geriatric population. The rising investment in the research and development activities for better treatment and the rise in most chronic diseases such as cancer, diabetes, cardiovascular disorders due to sedentary lifestyle, unhealthy diet, and lack of exercise are the major factors driving the Global Brain Biomarkers Market.

However, high capital investments, low cost-benefit ratio, and poorly suited regulatory and reimbursement systems are expected to hinder the growth of the brain biomarkers market.

Market Segmentation


The Global Brain Biomarkers Market is segmented further by Product, Indication, Application, End User & Geography.

By Product, the Global Brain Biomarkers market is classified into Biomarker Analyzers and Biomarker Test kits.

By Indication, the Global Brain Biomarkers market is classified into Alzheimer's Diseases and Dementia, Huntington's Disease, Parkinson's Disease, Stroke, MND, and ALS.

By Application, the Global Brain Biomarkers market is classified into Diagnosis, Drug Discovery, and Development.

By End User, the Global Brain Biomarkers market is classified into Hospitals, Diagnostic Laboratories, Research Laboratories, and Ambulatory Surgical Centres.

By Geography, North America is expected to lead the market.

Recent Developments

1. Biomarker predicts cognitive decline in Alzheimer's disease - 08th September 2021
2. Spinal Fluid Biomarkers Detect Neurodegeneration, Alzheimer's Disease in Living Patients - 20th July 2021

Company Profiles

Some of the companies covered in this report are Thermo Fisher Scientific Inc., Johnson & Johnson, Advanced Brain Monitoring, Abbott Laboratories, Siemens Healthnineers, GE Healthcare, Qiagen N.V., F. Hoffmann-La Roche Ltd., Perkinelmer, Inc., Quanterix Corporation, Nexus-DX, etc.

Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Brain Biomarkers Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Brain Biomarkers Market

What is the estimated value of the Global Brain Biomarkers Market?

The Global Brain Biomarkers Market was estimated to be valued at $6120 Million in 2021.

What is the growth rate of the Global Brain Biomarkers Market?

The growth rate of the Global Brain Biomarkers Market is 15.8%, with an estimated value of $12720 Million by 2026.

What is the forecasted size of the Global Brain Biomarkers Market?

The Global Brain Biomarkers Market is estimated to be worth $12720 Million by 2026.

Who are the key companies in the Global Brain Biomarkers Market?

Key companies in the Global Brain Biomarkers Market include Thermo Fisher Scientific Inc., Johnson & Johnson, Lifesign LLC, Advanced Brain Monitoring, Roche, Abbott Laboratories, Siemens Healthnineers, GE Healthcare and Qiagen N.V..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 IGR Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Overview
4.1 Drivers
4.1.1 High Prevalence of Brain Disorders Amongst Geriatric Population
4.1.2 Need for Invasive Brain Testing, Effective Drug Development, and New Treatment Option
4.1.3 Detection and Interpretation to Support Clinical Decisions and Patient Interventions
4.1.4 Increasing Investment in the Research and Development Activities for Better Treatment
4.2 Restraints
4.2.1 Expensive Clinical Validation and Lengthy Timelines for Biomarker Development
4.3 Opportunities
4.3.1 Recognition of Personalised Medicines
4.3.2 Incorporation of Detectable Parameters with Brain Biomarkers
4.4 Challenges
4.4.1 High Costs Involved in Biomarker Validation
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Brain Biomarkers Market, By Product
6.1 Introduction
6.2 Biomarker Analyzers
6.3 Biomarker Test kits
7 Global Brain Biomarkers Market, By Indication
7.1 Introduction
7.2 Alzheimer's Disease & Other Dementias
7.3 Huntington's Disease
7.4 MND & ALS
7.5 Parkinson's Disease
7.6 Stroke
8 Global Brain Biomarkers Market, By Application
8.1 Introduction
8.2 Diagnosis
8.3 Drug discovery
8.4 Development
9 Global Brain Biomarkers Market, By End User
9.1 Introduction
9.2 Ambulatory Surgical Centres
9.3 Diagnostic Laboratories
9.4 Hospitals
9.5 Research Laboratories
10 Global Brain Biomarkers Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 IGR Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 Thermo Fisher Scientific Inc.
12.2 Johnson & Johnson
12.3 Lifesign LLC
12.4 Advanced Brain Monitoring
12.5 Roche
12.6 Abbott Laboratories
12.7 Siemens Healthnineers
12.8 GE Healthcare
12.9 NeuroVista
12.10 Qiagen N.V.
12.11 Lifesign
12.12 F. Hoffmann-La Roche Ltd.
12.13 Natus Medical
12.14 NeuroVista
12.15 Electrical Geodesics
12.16 Perkinelmer, Inc.
12.17 Bio-Rad Laboratories, Inc.
12.18 Quanterix Corporation
12.19 Brainscope
12.20 Nexus-DX
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson
  • Lifesign LLC
  • Advanced Brain Monitoring
  • Roche
  • Abbott Laboratories
  • Siemens Healthnineers
  • GE Healthcare
  • NeuroVista
  • Qiagen N.V.
  • Lifesign
  • F. Hoffmann-La Roche Ltd.
  • Natus Medical
  • NeuroVista
  • Electrical Geodesics
  • Perkinelmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Quanterix Corporation
  • Brainscope
  • Nexus-DX